Wuppertal, Germany, January 29, 2026 – Aicuris (“Aicuris”) today announced that data from its pivotal Phase 3 trial (PRIOH-1) for pritelivir will be featured as a late-breaking oral presentation at the Tandem Meetings 2026, taking place on February 7 in Salt Lake City, USA. The novel helicase-primase inhibitor achieved its primary endpoint of complete lesion healing in immunocompromised patients with refractory herpes simplex virus (HSV) infections.
Complete abstracts are scheduled for release on February 4, 2026, at 7:00 am CET/1:00 am EST and will be accessible on the conference website.
Details of the Late-Breaking Oral Presentation:
Abstract Title: Pritelivir demonstrated superior efficacy compared to investigator’s choice treatment for refractory herpes simplex virus infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy
Presenting author: Genovefa Papanicolaou, MD, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, Cornell University, New York, USA
Date: Saturday, February 7, 2026
Time: 3:55 PM MST / 11:55 PM CET / 5:55 PM EST
About Pritelivir
Pritelivir is a novel helicase-primase inhibitor from Aicuris that is active against both HSV-1 and HSV-2. These viruses cause genital, oral, or widespread infections that are becoming more severe and have few treatment choices, especially in immunocompromised patients for whom antiviral resistance poses a major clinical problem. Pritelivir inhibits viral DNA synthesis by targeting the helicase-primase complex, a mechanism that differs from that of marketed nucleoside analogues. This unique mode of action enables pritelivir to be effective against strains that are resistant to nucleoside analog-based treatments.1 Prior clinical trials in both immunocompetent and immunocompromised individuals indicated a favorable safety profile and early signs of clinical efficacy versus standard care treatments such as valacyclovir and foscarnet. These findings led to the FDA granting pritelivir Breakthrough Therapy designation. Aicuris reported in October 2025 that pritelivir had met its primary endpoint in the pivotal Phase 3 trial. The company anticipates submitting a marketing authorization application to the U.S. FDA in 2026.
About Aicuris
Aicuris focuses on addressing the needs of the expanding immunocompromised population, which requires targeted therapies for effective infection treatment. The company’s flagship product, PREVYMIS®, which is marketed by partner MSD, provides cytomegalovirus (CMV) prevention for a specific group of transplant recipients. Aicuris’s pivotal Phase 3 candidate, pritelivir, is designed to treat refractory HSV infections in a wide range of patients with compromised immune systems. For immunocompromised individuals, an infection that is typically manageable can be life-threatening. Leveraging its expertise and expanding pipeline, Aicuris is dedicated to delivering therapeutic solutions for these patients both today and in the future.
Contact:
Aicuris Anti-infective Cures AG
info@aicuris.com
Trophic Communications
Dr. Stephanie May and Anja Heuer
Phone: +49 171 1855 682
Email:
1 Sallée, L. and Boutolleau, D. (2024), Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review. Rev Med Virol, 34: e2574.
Attachment
